more

ViewRay, Inc. (VRAY)

(Delayed Data from NSDQ)

$7.96 USD

+1.19 (17.58%)

Updated May 3, 2019 04:00 PM ET

After-Market: $7.91 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.03%
2	Buy	17.70%
3	Hold	9.37%
4	Sell	5.03%
5	Strong Sell	2.48%
S&P	500	11.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Industry: NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

ViewRay (VRAY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research Published on March 05,2020

ViewRay (VRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VRAYPositive Net Change

ViewRay Allies With Two Majors in MR-Guided Radiation Therapy

by Zacks Equity Research Published on December 03,2019

ViewRay's (VRAY) collective investments from Elekta and Medtronic are conditioned to the consummation of an equity capital hike of at least $75 million.

Options Traders Expect Huge Moves in ViewRay (VRAY) Stock

by Zacks Equity Research Published on November 21,2019

Investors need to pay close attention to ViewRay (VRAY) stock based on the movements in the options market lately.

VRAYPositive Net Change

medical

ViewRay (VRAY) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on November 12,2019

ViewRay (VRAY) delivered earnings and revenue surprises of 22.22% and 0.35%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

VRAYPositive Net Change

ViewRay (VRAY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research Published on November 05,2019

ViewRay (VRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VRAYPositive Net Change

What's in Store for GW Pharmaceuticals (GWPH) in Q3 Earnings?

by Zacks Equity Research Published on October 30,2019

Developments in Epidolex are likely to have aided GW Pharmaceuticals' (GWPH) performance in the third quarter.

medical

What's in the Cards for Zimmer Biomet's (ZBH) Q3 Earnings?

by Zacks Equity Research Published on October 29,2019

In Spine & CMF, Zimmer Biomet (ZBH) is witnessing slowdown in growth due to difficult comps.

Can Overall Growth Boost Boston Scientific (BSX) Q3 Earnings?

by Zacks Equity Research Published on October 21,2019

We are once again optimistic about the IC business of Boston Scientific (BSX), which is likely to have aided the company to retain impressive global growth in Q3.

medical

What's in the Offing for LabCorp's (LH) Earnings in Q3?

by Zacks Equity Research Published on October 21,2019

LabCorp (LH) is expected to have advanced its companion diagnostics and oncology capabilities in the third quarter.

medical

Are Options Traders Betting on a Big Move in ViewRay (VRAY) Stock?

by Zacks Equity Research Published on September 13,2019

Investors need to pay close attention to ViewRay (VRAY) stock based on the movements in the options market lately.

VRAYPositive Net Change

medical

Is the Options Market Predicting a Spike in ViewRay (VRAY) Stock?

by Zacks Equity Research Published on August 12,2019

Investors need to pay close attention to ViewRay (VRAY) stock based on the movements in the options market lately.

VRAYPositive Net Change

medical

ViewRay (VRAY) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on August 08,2019

ViewRay (VRAY) delivered earnings and revenue surprises of -39.13% and 12.57%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

VRAYPositive Net Change

Will ViewRay (VRAY) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research Published on August 01,2019

ViewRay (VRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VRAYPositive Net Change

ViewRay (VRAY) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research Published on May 02,2019

ViewRay (VRAY) delivered earnings and revenue surprises of -54.55% and -3.30%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

VRAYPositive Net Change

Analysts Estimate ViewRay (VRAY) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research Published on April 25,2019

ViewRay (VRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.